BeiGene Net Change in Intangible Assets 2014-2024 | ONC
BeiGene annual/quarterly net change in intangible assets history and growth rate from 2014 to 2024. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.
- BeiGene net change in intangible assets for the quarter ending September 30, 2024 was $-0.005B, a 50.35% decline year-over-year.
- BeiGene net change in intangible assets for the twelve months ending September 30, 2024 was $-0.033B, a 254.69% increase year-over-year.
- BeiGene annual net change in intangible assets for 2023 was $-0.019B, a INF% decline from 2022.
- BeiGene annual net change in intangible assets for 2022 was $0B, a 100% decline from 2021.
- BeiGene annual net change in intangible assets for 2021 was $-0.043B, a INF% decline from 2020.
BeiGene Annual Net Change in Intangible Assets
(Millions of US $) |
| 2023 |
$-19 |
| 2022 |
$ |
| 2021 |
$-43 |
| 2020 |
$ |
| 2019 |
$ |
| 2018 |
$-1 |
| 2017 |
$-12 |
| 2016 |
$ |
| 2015 |
$ |
| 2014 |
$ |
| 2013 |
$ |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
